Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: ...

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

Moderna’s top executives have sought to reassure investors they will be able to carry out the comeback plans announced in ...

Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

Analyst Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report) and decreased the price target to $50.00 from $55.00. Don't Miss our Black Friday Offers: Unlock your ...

CNBC's Jim Cramer reports on the latest news regarding Moderna.

Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other biotech stocks. Biotechnology stocks are among the most volatile in the market due to ...

Coegi used more than 500 million impressions and paid social optimized with attention and emotion metrics to drive 24% of ...

Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.

Investing.com -- Shares of Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) were up roughly 7% at $41, while those of Pfizer Inc (NYSE:PFE)were up nearly 2%. Jefferies analysts said Investor sentiment around ...